[Preparation and characterization of specific monoclonal antibodies against HER2].
OBJECTIVE
To prepare and characterize the specific monoclonal antibodies (mAbs) that can recognize the native conformation of HER2 so as to guide the clinical application of Herceptin.


METHODS
Hybridomas were generated by the fusion with the NS1 myeloma cell and spleen cell, which were from mice immunized by HER2 recombinant protein. After cell fusion, ELISA, Yeast cell base ELISA and immunohistochemistry were used to screening clones respectively.


RESULTS
Eight clones that could react with SK-Br-3 and yeast displaying HER2 were selected from 168 clones which were positive in initial screening by ELISA.


CONCLUSIONS
Successfully prepared 8 mAbs that can recognize the native conformation of HER2, which should provide useful reagent for personalized therapy against breast cancer with Herceptin.
Liu
Hong-qin
HQ
Union Stem Cell &Gene Engineering Co., Ltd., Tianjin 300384, China.
Wang
Dong-mei
DM
Qu
Hao
H
Shi
Lin
L
Huang
Li-hua
LH
Feng
Chun-ling
CL
Zhang
Li-yan
LY
Zhu
Wei-bin
WB
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000276:immunology* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity; D045744:Cell Line, Tumor; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006825:Hybridomas; D007150:Immunohistochemistry; D051379:Mice; D008807:Mice, Inbred BALB C; D011487:Protein Conformation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000737:chemistry / Q000276:immunology*; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab